• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Innocoll Biotherapeutics initiates Phase 3 trials for collagen drug-device

April 14, 2021 By Sean Whooley

InnocollInnocoll Biotherapeutics announced today that it initiated two Phase 3 trials to support a label expansion for its collagen drug-device implant.

Athlone, Ireland-based Innocoll’s trials are seeking label expansion for the FDA-approved Xaracoll (bupivacaine hydrochloride) implant, according to a news release.

INN-CB-024, a Phase 3, randomized, double-blind, placebo-controlled study is evaluating the efficacy and safety of a 300mg dose of the INL-001 implant in patients undergoing abdominoplasty. INN-CB-025 is a Phase 3 open-label study of the safety and pharmacokinetics of the INL-001 implant in adults following various open soft-tissue surgeries, including open ventral hernia repair, abdominoplasty, open abdominal hysterectomy, laparoscopic-assisted colectomy, and reduction mammoplasty.

Both trials are screening and enrolling patients at present, with the expectation of being fully enrolled by the end of 2021 with results expected in the first quarter of 2022.

“We are thrilled to announce that our non-opioid, fully bioresorbable collagen drug-device product, Xaracoll, which is currently an approved treatment option for acute postsurgical pain following open inguinal hernia repair in adults, has reached the important milestone of being studied in Phase 3 clinical trials for use in soft tissue surgeries,” Innocoll CEO & president Louis Pascarella said in the release. “Following the clinical success of Xaracoll in open inguinal hernia repair and building upon the supportive Phase 2 data in other soft tissue surgeries, Innocoll is now undertaking the important work of studying the efficacy and safety of Xaracoll in achieving post-surgical pain relief in patients undergoing other soft tissue surgeries.

“We look forward to sharing data on these studies as we continue to expand the body of clinical data for Xaracoll and develop our unique drug-device combination product for use in additional surgeries.”

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Surgical Tagged With: innocoll

IN CASE YOU MISSED IT

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS